[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer
- PMID: 29791503
- PMCID: PMC5965848
- DOI: 10.1371/journal.pone.0197754
[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer
Abstract
Rationale: Pathological response to neo-adjuvant chemotherapy (NAC) represents a commonly used predictor of survival in triple negative breast cancer (TNBC) and the need to identify markers that predict response to NAC is constantly increasing. Aim of this study was to evaluate the potential usefulness of PET imaging with [18F]FDG and [18F]FLT for the discrimination of TNBC responders to Paclitaxel (PTX) therapy compared to the response assessed by an adapted Response Evaluation Criteria In Solid Tumors (RECIST) criteria based on tumor volume (Tumor Volume Response).
Methods: Nu/nu mice bearing TNBC lesions of different size were evaluated with [18F]FDG and [18F]FLT PET before and after PTX treatment. SUVmax, Metabolic Tumor Volume (MTV) and Total Lesion Glycolysis (TLG) and Proliferation (TLP) were assessed using a graph-based random walk algorithm.
Results: We found that in our TNBC model the variation of [18F]FDG and [18F]FLT SUVmax similarly defined tumor response to therapy and that SUVmax variation represented the most accurate parameter. Response evaluation using Tumor Volume Response (TVR) showed that the effectiveness of NAC with PTX was completely independent from lesions size at baseline.
Conclusions: Our study provided interesting results in terms of sensitivity and specificity of PET in TNBC, revealing the similar performances of [18F]FDG and [18F]FLT in the identification of responders to Paclitaxel.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures





Similar articles
-
Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1279-1288. doi: 10.1007/s00259-018-3998-z. Epub 2018 Apr 4. Eur J Nucl Med Mol Imaging. 2018. PMID: 29616304
-
Early prediction of triple negative breast cancer response to cisplatin treatment using diffusion-weighted MRI and 18F-FDG-PET.Breast Cancer. 2018 May;25(3):334-342. doi: 10.1007/s12282-018-0834-z. Epub 2018 Jan 22. Breast Cancer. 2018. PMID: 29357023
-
Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.Eur J Cancer. 2014 Jul;50(11):1864-71. doi: 10.1016/j.ejca.2014.04.020. Epub 2014 May 16. Eur J Cancer. 2014. PMID: 24841218
-
FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.Breast. 2013 Oct;22(5):691-7. doi: 10.1016/j.breast.2012.12.020. Epub 2013 Feb 12. Breast. 2013. PMID: 23414930
-
PET imaging of cellular proliferation.Radiol Clin North Am. 2005 Jan;43(1):153-67. doi: 10.1016/j.rcl.2004.09.005. Radiol Clin North Am. 2005. PMID: 15693654 Review.
Cited by
-
A New Preclinical Decision Support System Based on PET Radiomics: A Preliminary Study on the Evaluation of an Innovative 64Cu-Labeled Chelator in Mouse Models.J Imaging. 2022 Mar 30;8(4):92. doi: 10.3390/jimaging8040092. J Imaging. 2022. PMID: 35448219 Free PMC article.
-
Advances in PET Diagnostics for Guiding Targeted Cancer Therapy and Studying In Vivo Cancer Biology.Curr Pathobiol Rep. 2019 Sep;7(3):97-108. doi: 10.1007/s40139-019-00202-9. Epub 2019 Jul 25. Curr Pathobiol Rep. 2019. PMID: 37092138 Free PMC article.
-
Machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy.Breast. 2020 Feb;49:115-122. doi: 10.1016/j.breast.2019.11.009. Epub 2019 Nov 23. Breast. 2020. PMID: 31786416 Free PMC article. Review.
-
Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models.Contrast Media Mol Imaging. 2019 Sep 22;2019:8946729. doi: 10.1155/2019/8946729. eCollection 2019. Contrast Media Mol Imaging. 2019. PMID: 31598114 Free PMC article. Review.
-
Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response.J Clin Med. 2023 Dec 27;13(1):154. doi: 10.3390/jcm13010154. J Clin Med. 2023. PMID: 38202160 Free PMC article. Review.
References
-
- Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, et al. (2015) Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget 6: 12890–12908. doi: 10.18632/oncotarget.3849 - DOI - PMC - PubMed
-
- Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, et al. (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26: 1275–1281. - PubMed
-
- von Minckwitz G (2012) Pathologic complete response after neoadjuvant therapy of breast cancer: pitfalls and shortcomings. Breast cancer research and treatment 132: 779–780. doi: 10.1007/s10549-012-2029-1 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials